Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse

Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapseПодробнее

Management of relapse following alloHSCT in patients with AML and MDSПодробнее

Preventing relapse post-transplant in AML and MDS?Подробнее

Novel Strategies to Prevent Relapse after Allogeneic Transplantation for MDSПодробнее

Prevention, detection and treatment of AML relapse after allo-SCTПодробнее

Outcomes & treatment options for patients with AML who relapse after alloHSCTПодробнее

Are hypomethylating agents useful in preventing relapse in AML and MDS?Подробнее

Emerging strategies for the management of relapsed AMLПодробнее

The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)Подробнее

Conditioning intensity and genomics: relapse after allogeneic transplant in MDSПодробнее

Managing ALL patients who relapse after transplantationПодробнее

Unanswered questions in AML: classification, the role of chemotherapy & avoiding relapseПодробнее

AML relapse after HSCT: trends and predictive factorsПодробнее

Managing disease relapse in transplant patients with AMLПодробнее

The use of DLI to prevent relapseПодробнее

High-grade vs low-grade chemotherapy in patients with relapsed AML or MDSПодробнее

AML Indications for Transplantation and Treatment of RelapseПодробнее

Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated diseaseПодробнее

Investigating relapse after allo-SCT in AMLПодробнее

Treatments to prevent relapse in AMLПодробнее